Arrowhead Pharmaceuticals Launches REDEMPLO® (plozasiran) with Disruptive $60,000 Annual Price, Challenging Market Leader in Rare Lipid Disorder
Ionis Pharmaceuticals
RNA Drug Developer
Sanofi
Pharmaceutical Manufacturer
Visirna
siRNA Drug Developer
On November 18, 2025, the biopharmaceutical industry reached a milestone moment — Arrowhead Pharmaceuticals officially announced that its重磅 siRNA drugREDEMPLO®（plozasiran）Received U.S. FDA approval as an adjunct to diet for the treatment of adult patients with familial chylomicronemia syndrome (FCS).
According to the company's official press release,REDEMPLO is the first and only RNAi therapy approved by the FDA for FCS.Patients only need to receive a subcutaneous injection once every three months.The wholesale procurement cost disclosed by the company (WAC) is priced at $60,000 per year and adopts a "uniform pricing" model.This move marks Arrowhead Pharmaceuticals' successful transformation from a research and development biotechnology company to a biopharmaceutical enterprise with commercialized products.
The approval was based on positive data from the Phase III PALISADE trial, showing that plozasiran significantly reduced triglyceride levels by up to 80% in patients with FCS. Industry media Fierce Pharma analysis pointed out that the launch of REDEMPLO and itsAggressive pricing at only one-tenth of competitors, which will directly challenge Ionis Pharmaceuticals' antisense oligonucleotide (ASO) drug Olezarsen (with an annual price tag of up to $595,000), signaling intensified competition in the treatment of rare lipid metabolism disorders.
In August 2025, Sanofi entered into an asset purchase agreement with Visirna Therapeutics, a subsidiary of Arrowhead Pharmaceuticals, to obtain the rights to develop and commercialize plozasiran in Greater China. According to the agreement, Visirna will receive$130 million upfront payment, and is eligible to receive up to after plozasiran is approved for various indications in mainland China.Additional milestone payments of $265 million。
As Arrowhead Pharmaceuticals' first commercial product, plozasiran is highly anticipated by the company. Its success not only fills a clinical gap but also paves the way for the company's subsequent pipeline.
In terms of commercialization strategy, Arrow Pharmaceuticals has adopted a clear"From Small to Large" Path:First, tackle the rare disease market of FCS, establishing clinical reputation and reimbursement templates; then expand the target to the larger patient population of Severe Hypertriglyceridemia (SHTG). This strategy not only allows for rapid market entry through rare diseases but also reserves significant room for future revenue growth.
In terms of pricing, Arrow Pharmaceuticals has adopted a disruptive market strategy. Its announced annually$60,000 "Flat Rate," Significantly Lower Than CompetitorsThis may not only accelerate the coverage of medical insurance and patient accessibility, but also provide price elasticity when subsequently expanding to the larger patient base of SHTG indications. Analysts believe that this wise pricing strategy is key to capturing market share.
The deeper significance lies in the fact that plozasiran has validated the maturity of Arrowhead Pharmaceuticals' technology platform. Its collaboration with Sarepta Therapeutics on the ARO-DM1 therapy for Type 1 Myotonic Dystrophy (DM1) triggered a $100 million milestone payment in July 2025, further demonstrating the platform's potential in extrhepatic tissue applications. This lays the groundwork for subsequent pipeline development targeting central nervous system disorders and obesity.
Arrowhead's 2025 semi-annual report shows that the company's revenue for the second quarter was $543 million, and the revenue for the third quarter was $27.76 million, with R&D expenses increasing year-on-year to $193 million (Arrowhead Pharmaceuticals, 2025 Q2/Q3 Report). This data reflects its focus on pipeline advancement, particularly the commercialization preparation for REDEMPLO.
Arrowhead's financial stability has been significantly strengthened due to its collaboration with Sarepta. This partnership not only provided short-term financial support but also injected certainty into the company’s long-term development.
The partnership with Sarepta strengthens its financial position, funding operations through 2028 and covering multiple potential commercial launches. Additionally, Arrowhead Pharmaceuticals has garnered over $2 billion in revenue from the collaboration, providing financial flexibility.
Recently, the company has further deepened its cooperation with Sarepta. In July 2025, Arrowhead Pharmaceuticals' investigational RNAi therapy (SRP-1003 or ARO-DM1) for Type 1 Myotonic Dystrophy (DM1) achieved its first enrollment target in a Phase 1/2 clinical trial, triggering a $100 million milestone payment from Sarepta.
Analysts pointed out that REDEMPLO's pricing strategy ($60,000/year) may provide revenue elasticity for subsequent indications (such as hypertriglyceridemia).
Currently, there are a total ofSeven small interfering RNA (siRNA) drugs have been approved for marketing.
Compiled by Qiu Shi Pharmacy
At the same time, Chinese pharmaceutical companies are also rapidly advancing in the siRNA field,China has not yet independently developedsiRNA Drug Approved for Marketing, but many pharmaceutical companies have already laid out this cutting-edge field, and some drugs under research have entered the clinical trial stage.
Compiled by Qiu Shi Pharmacy
Overall, the current research and development of siRNA drugs in China presents some distinct characteristics:
Focus on Common Chronic Diseases:Unlike global early siRNA drugs that mostly target rare diseases, the R&D pipelines of pharmaceutical companies in China focus more onHypertension, Gout, Hepatitis B, HyperlipidemiaIn common disease areas with a large patient base, this is more in line with China's disease spectrum and market characteristics.
Technology Platform Becomes Core Competitiveness:The core challenge of siRNA drugs lies in the delivery system. Currently,GalNAc (N-Acetylgalactosamine) Liver-Targeted Delivery TechnologyHas become the mainstream platform for drugs under research for hepatic diseases. In addition, domestic companies such asSino BiologicsMoreover, due to its innovative hepatic delivery technology, it reached an agreement with Eli Lilly for a total amount up to$1.2 billionThe strategic cooperation highlights the international recognition of its technical strength.
"Bring In" and "Go Global": On the one hand, through a model similar to Sanofi's introduction of plozasiran, global innovative therapies are rapidly brought into China; on the other hand, local enterprises also actively promote their own intellectual property pipelines globally through overseas licensing (BD). For example,Bowang Pharmaceuticalshas reached a deal with Novartis for up to$9.3 billionThe strategic cooperation has set a new record for BD transactions in China's biotechnology companies.
With the successful launch of plozasiran, the commercial potential of siRNA therapy has been further validated. However, this track is full of both opportunities and challenges.
A huge market space is opening upNovartis' siRNA drug Leqvio (inclisiran) generated $555 million in revenue in the first half of 2025, representing a 66% year-over-year increase, fully demonstrating the commercial value of such drugs in chronic disease management. The expansion from rare diseases to common diseases has become a clear industry trend.
However, the technical challenges remain severe.The development of siRNA drugs is a complex systematic project, involving multiple dimensions such as sequence design, chemical modification, and delivery system optimization. Among these,Targeted Delivery to Extrahepatic TissuesIt remains a technical bottleneck that the industry urgently needs to break through. Whoever achieves a breakthrough in this field first will occupy the commanding heights of the next generation of siRNA therapy.
Disclaimer:
The content of the article is for reference only and does not constitute investment advice. Investors who take actions based on this information bear their own risks. The article maintains a neutral stance on the statements and viewpoints expressed, and does not provide any explicit or implicit guarantees regarding the accuracy, reliability, or completeness of the content contained within. Readers are advised to use it solely as a reference and assume full responsibility for their actions.
I-RNA
Small Nucleic Acid2026
Booths are booking up fast!
Scan to consult immediately
Phone: 13816031174
(Same as WeChat)